Iris Biotechnologies (IRSB) 0.1400 $IRSB Iris B
Post# of 273319
Posted On: 06/22/2016 6:15:30 PM
Iris Biotechnologies (IRSB) 0.1400 $IRSB
Iris BioTechnologies Announces Its BioWindows 3-Risk Scores System for Multi-Omic Analysis in the War Against Cancer and Other Diseases
Marketwire Canada - Mon May 23, 3:40PM CDT
SANTA CLARA, CA--(Marketwired - May 23, 2016) - Iris BioTechnologies Inc. (OTC PINK: IRSB) announces its BioWindows™ 3-Risk Scores System for Multi-Omic Analysis, which will be offered through its subsidiary, Iris Wellness Labs. The System performs intricate correlations, while presenting results in a user-friendly visual format, allowing physicians and patients to understand and act on complex molecular information.
Iris BioTechnologies Inc. Reports on Legal Proceedings Involving Heller Ehrman LLP
Marketwired - Wed Nov 25, 12:18PM CST
On November 20, 2015, the Ninth Circuit Court of Appeals affirmed the lower court decision denying Iris's motion to file a malpractice claim against its former legal counsel Heller Ehrman LLP. Heller Ehrman was a reputable, one-hundred-plus-years-old law firm with more than 600 attorneys. Heller Ehrman was Iris BioTechnologies' patent counsel from February 1999 to September 2011.
Hanson McClain Filed False Reports With the Security and Exchange Commission Regarding Iris BioTechnologies
Marketwire Canada - Mon Mar 30, 12:28PM CDT
Hanson McClain Advisors, a Sacramento based financial advisory firm, has submitted a series of false filings with the Security and Exchange Commission (SEC) about Iris BioTechnologies Inc. (OTCQB: IRSB).
Iris BioTechnologies Welcomes New Board Member and Key Employees
Marketwired - Tue Jan 27, 7:23PM CST
Iris BioTechnologies Inc. (OTCQB: IRSB), a life sciences company poised to set new personalized medicine standards for precision diagnosis and therapy, is pleased to welcome Dr. Douglas Hendren, Dr. John Hearst, Dr. Frank Chuang, and Gayle Murray to our team at a very exciting time in the growth of our company. In the State of the Union speech on January 20, 2015, President Obama said, "Personalized medicine represents a revolutionary and exciting change in the fundamental approach and practice of medicine."
Iris BioTechnologies Announces Its BioWindows 3-Risk Scores System for Multi-Omic Analysis in the War Against Cancer and Other Diseases
Marketwire Canada - Mon May 23, 3:40PM CDT
SANTA CLARA, CA--(Marketwired - May 23, 2016) - Iris BioTechnologies Inc. (OTC PINK: IRSB) announces its BioWindows™ 3-Risk Scores System for Multi-Omic Analysis, which will be offered through its subsidiary, Iris Wellness Labs. The System performs intricate correlations, while presenting results in a user-friendly visual format, allowing physicians and patients to understand and act on complex molecular information.
Iris BioTechnologies Inc. Reports on Legal Proceedings Involving Heller Ehrman LLP
Marketwired - Wed Nov 25, 12:18PM CST
On November 20, 2015, the Ninth Circuit Court of Appeals affirmed the lower court decision denying Iris's motion to file a malpractice claim against its former legal counsel Heller Ehrman LLP. Heller Ehrman was a reputable, one-hundred-plus-years-old law firm with more than 600 attorneys. Heller Ehrman was Iris BioTechnologies' patent counsel from February 1999 to September 2011.
Hanson McClain Filed False Reports With the Security and Exchange Commission Regarding Iris BioTechnologies
Marketwire Canada - Mon Mar 30, 12:28PM CDT
Hanson McClain Advisors, a Sacramento based financial advisory firm, has submitted a series of false filings with the Security and Exchange Commission (SEC) about Iris BioTechnologies Inc. (OTCQB: IRSB).
Iris BioTechnologies Welcomes New Board Member and Key Employees
Marketwired - Tue Jan 27, 7:23PM CST
Iris BioTechnologies Inc. (OTCQB: IRSB), a life sciences company poised to set new personalized medicine standards for precision diagnosis and therapy, is pleased to welcome Dr. Douglas Hendren, Dr. John Hearst, Dr. Frank Chuang, and Gayle Murray to our team at a very exciting time in the growth of our company. In the State of the Union speech on January 20, 2015, President Obama said, "Personalized medicine represents a revolutionary and exciting change in the fundamental approach and practice of medicine."
(0)
(0)